An inactivated recombinant rabies virus chimerically expressed RBD induces humoral and cellular immunity against SARS-CoV-2 and RABV.
Chimeric expression
RABV
RBD
SARS-CoV-2
Vaccine
Journal
Virologica Sinica
ISSN: 1995-820X
Titre abrégé: Virol Sin
Pays: Netherlands
ID NLM: 101514185
Informations de publication
Date de publication:
Apr 2023
Apr 2023
Historique:
received:
12
09
2022
accepted:
26
12
2022
medline:
3
5
2023
pubmed:
2
1
2023
entrez:
1
1
2023
Statut:
ppublish
Résumé
Many studies suggest that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can infect various animals and transmit among animals, and even to humans, posing a threat to humans and animals. There is an urgent need to develop inexpensive and efficient animal vaccines to prevent and control coronavirus disease 2019 (COVID-19) in animals. Rabies virus (RABV) is another important zoonotic pathogen that infects almost all warm-blooded animals and poses a great public health threat. The present study constructed two recombinant chimeric viruses expressing the S1 and RBD proteins of the SARS-CoV-2 Wuhan01 strain based on a reverse genetic system of the RABV SRV9 strain and evaluated their immunogenicity in mice, cats and dogs. The results showed that both inactivated recombinant viruses induced durable neutralizing antibodies against SARS-CoV-2 and RABV and a strong cellular immune response in mice. Notably, inactivated SRV-nCoV-RBD induced earlier antibody production than SRV-nCoV-S1, which was maintained at high levels for longer periods. Inactivated SRV-nCoV-RBD induced neutralizing antibodies against both SARS-CoV-2 and RABV in cats and dogs, with a relatively broad-spectrum cross-neutralization capability against the SARS-CoV-2 pseudoviruses including Alpha, Beta, Gamma, Delta, and Omicron, showing potential to be used as a safe bivalent vaccine candidate against COVID-19 and rabies in animals.
Identifiants
pubmed: 36587795
pii: S1995-820X(22)00212-7
doi: 10.1016/j.virs.2022.12.006
pmc: PMC9797420
pii:
doi:
Substances chimiques
Antibodies, Viral
0
Rabies Vaccines
0
Antibodies, Neutralizing
0
Spike Glycoprotein, Coronavirus
0
spike protein, SARS-CoV-2
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
244-256Informations de copyright
Copyright © 2023 The Authors. Publishing services by Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Conflict of interest The authors declare no conflicts of interest, financial or otherwise.
Références
PLoS One. 2018 Nov 12;13(11):e0207295
pubmed: 30419070
Nature. 2020 Oct;586(7830):594-599
pubmed: 32998157
Lancet. 2022 Mar 12;399(10329):1070-1078
pubmed: 35279259
PLoS Negl Trop Dis. 2021 Jun 4;15(6):e0009484
pubmed: 34086672
J Virol. 2017 Mar 29;91(8):
pubmed: 28148801
mBio. 2020 Oct 13;11(5):
pubmed: 33051368
Clin Infect Dis. 2022 Aug 24;75(1):e76-e81
pubmed: 35234870
Emerg Microbes Infect. 2020 Dec;9(1):680-686
pubmed: 32207377
Emerg Infect Dis. 2022 Jul;28(7):1485-1488
pubmed: 35666777
Nat Commun. 2020 Mar 27;11(1):1620
pubmed: 32221306
Virus Genes. 2015 Apr;50(2):299-302
pubmed: 25724175
Nat Med. 2022 Mar;28(3):486-489
pubmed: 35051989
JAMA Netw Open. 2022 May 2;5(5):e2212073
pubmed: 35560054
J Virol Methods. 2019 Aug;270:46-51
pubmed: 31047970
Science. 2020 Mar 13;367(6483):1260-1263
pubmed: 32075877
Elife. 2020 Oct 28;9:
pubmed: 33112236
Nature. 2021 Aug;596(7872):417-422
pubmed: 34192737
Mol Ther. 2019 Apr 10;27(4):757-772
pubmed: 30803823
Nature. 2020 Aug;584(7819):120-124
pubmed: 32454512
Science. 2021 Jan 8;371(6525):172-177
pubmed: 33172935
EMBO J. 1994 Sep 15;13(18):4195-203
pubmed: 7925265
Nature. 2020 Oct;586(7830):578-582
pubmed: 32731258
J Immunol Methods. 1998 Mar 1;212(1):79-87
pubmed: 9671155
J Virol. 2017 Jan 3;91(2):
pubmed: 27807241
Viruses. 2020 Nov 18;12(11):
pubmed: 33218001
Front Immunol. 2022 Jan 31;13:823949
pubmed: 35173733
Nature. 2022 Jul;607(7918):351-355
pubmed: 35584773
Viruses. 2022 May 24;14(6):
pubmed: 35746599
Science. 2020 Jul 3;369(6499):77-81
pubmed: 32376603
Cytokine Growth Factor Rev. 2007 Feb-Apr;18(1-2):195-207
pubmed: 17347024
Cell Commun Signal. 2020 Sep 18;18(1):153
pubmed: 32948206
EBioMedicine. 2017 Oct;24:195-204
pubmed: 28970080
Nature. 2020 Oct;586(7830):572-577
pubmed: 32726802
Front Vet Sci. 2017 Feb 10;4:9
pubmed: 28239608
Nat Rev Immunol. 2021 Feb;21(2):73-82
pubmed: 33340022
Signal Transduct Target Ther. 2022 May 3;7(1):146
pubmed: 35504917
Viruses. 2019 Dec 03;11(12):
pubmed: 31816996
Nature. 2020 Oct;586(7830):589-593
pubmed: 32785213
Nat Commun. 2018 Oct 11;9(1):4223
pubmed: 30310067
Lancet. 2020 Aug 15;396(10249):479-488
pubmed: 32702299
Lancet Infect Dis. 2021 Jan;21(1):39-51
pubmed: 33069281
J Immunol. 2000 May 1;164(9):4507-12
pubmed: 10779751
Viruses. 2020 Jan 20;12(1):
pubmed: 31968702
Lancet Microbe. 2022 May;3(5):e348-e356
pubmed: 35345417
Viruses. 2019 Oct 08;11(10):
pubmed: 31597372
NPJ Vaccines. 2020 Oct 16;5:98
pubmed: 33088593
J Virol. 2003 Oct;77(20):10889-99
pubmed: 14512539
Cell. 2021 Mar 4;184(5):1171-1187.e20
pubmed: 33621484
Cell Host Microbe. 2020 May 13;27(5):704-709.e2
pubmed: 32259477
Front Immunol. 2022 Feb 07;13:821664
pubmed: 35197985
Virol Sin. 2017 Jun;32(3):207-215
pubmed: 28634871
Int J Mol Sci. 2020 Jul 06;21(13):
pubmed: 32640747
Science. 2020 May 29;368(6494):1016-1020
pubmed: 32269068
Cell. 2022 Jun 23;185(13):2265-2278.e14
pubmed: 35568034
J Virol Methods. 2009 Oct;161(1):58-62
pubmed: 19481115
Transbound Emerg Dis. 2022 Sep;69(5):e2516-e2529
pubmed: 35544742
PLoS Pathog. 2021 Mar 25;17(3):e1009383
pubmed: 33765062
Front Immunol. 2021 Nov 05;12:744242
pubmed: 34804024
Cell Rep. 2021 Apr 20;35(3):109017
pubmed: 33857422
PLoS One. 2012;7(6):e38630
pubmed: 22719908
J Infect Dis. 2015 Oct 1;212 Suppl 2:S414-24
pubmed: 26063224
Front Microbiol. 2020 Feb 28;11:298
pubmed: 32265848